Use of C-type natriuretic peptide variants to treat skeletal dysplasia

US10646550B2 · kind B2 · utility

Assignee

• BIOMARIN PHARMACEUTICAL INC. · US

Inventors

• Sherry Bullens · Novato, US
• Stuart Bunting · Novato, US
• Tianwei Chou · Novato, US
• Augustus O. Okhamafe · Concord, US
• Christopher P. Price · Aachen, DE
• Daniel J. Wendt · Novato, US
• Clarence Yap · Novato, US

Key dates

• Filing date: Jan 25, 2018
• Grant date: May 12, 2020
• Expiry date: Jan 25, 2038

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61P19/08
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present disclosure provides for use of variants of C-type natriuretic peptide (CNP), and novel pharmaceutical compositions and formulations comprising CNP variant peptides for the treatment of skeletal dysplasias, one or more symptoms of skeletal dysplasias, such as long bone growth or growth velocity, and other disorders having a skeletal dysplasia and/or CNP-associated symptom or component.